Kodiak Sciences annual free cash flow
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Kodiak Sciences Free Cash Flow (FCF) History (KOD)
Kodiak Sciences reported −$136.5M in free cash flow for fiscal 2025, a decrease of $18.8M from the previous fiscal year.
View full Kodiak Sciences company overviewKodiak Sciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$136.5M | −$18.8M | — | — |
| 2024 | 2024-12-31 | −$117.7M | $77.8M | — | — |
| 2023 | 2023-12-31 | −$195.5M | $47.9M | — | — |
| 2022 | 2022-12-31 | −$243.5M | −$44.2M | — | — |
| 2021 | 2021-12-31 | −$199.3M | −$112.1M | — | — |
| 2020 | 2020-12-31 | −$87.2M | −$47.7M | — | — |
| 2019 | 2019-12-31 | −$39.6M | −$10.5M | — | — |
| 2018 | 2018-12-31 | −$29.1M | −$11.2M | — | — |
| 2017 | 2017-12-31 | −$17.9M | −$1.0M | — | — |
| 2016 | 2016-12-31 | −$16.8M | — | — | — |
Kodiak Sciences quarterly free cash flow
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$46.6M | −$11.8M | — | — |
| Q1 2026 | 2026-03-31 | −$41.0M | −$11.6M | — | — |
| Q4 2025 | 2025-12-31 | −$39.4M | −$9.2M | — | — |
| Q3 2025 | 2025-09-30 | −$32.9M | −$11.6M | — | — |
| Q2 2025 | 2025-06-30 | −$34.8M | −$8.3M | — | — |
| Q1 2025 | 2025-03-31 | −$29.3M | $10.3M | — | — |
| Q4 2024 | 2024-12-31 | −$30.2M | $29.5M | — | — |
| Q3 2024 | 2024-09-30 | −$21.3M | $11.7M | — | — |
| Q2 2024 | 2024-06-30 | −$26.5M | $16.9M | — | — |
| Q1 2024 | 2024-03-31 | −$39.6M | $19.8M | — | — |
| Q4 2023 | 2023-12-31 | −$59.7M | −$1.6M | — | — |
| Q3 2023 | 2023-09-30 | −$33.0M | $28.4M | — | — |
| Q2 2023 | 2023-06-30 | −$43.4M | $19.9M | — | — |
| Q1 2023 | 2023-03-31 | −$59.4M | $1.2M | — | — |
| Q4 2022 | 2022-12-31 | −$58.1M | $9.3M | — | — |
| Q3 2022 | 2022-09-30 | −$61.4M | −$4.6M | — | — |
| Q2 2022 | 2022-06-30 | −$63.4M | −$24.2M | — | — |
| Q1 2022 | 2022-03-31 | −$60.6M | −$24.8M | — | — |
| Q4 2021 | 2021-12-31 | −$67.5M | −$38.5M | — | — |
| Q3 2021 | 2021-09-30 | −$56.8M | −$30.6M | — | — |
| Q2 2021 | 2021-06-30 | −$39.2M | −$25.2M | — | — |
| Q1 2021 | 2021-03-31 | −$35.9M | −$17.8M | — | — |
| Q4 2020 | 2020-12-31 | −$29.0M | −$17.5M | — | — |
| Q3 2020 | 2020-09-30 | −$26.2M | −$18.3M | — | — |
| Q2 2020 | 2020-06-30 | −$14.0M | −$905,000 | — | — |
| Q1 2020 | 2020-03-31 | −$18.1M | −$10.9M | — | — |
| Q4 2019 | 2019-12-31 | −$11.4M | −$3.1M | — | — |
| Q3 2019 | 2019-09-30 | −$7.9M | −$2.9M | — | — |
| Q2 2019 | 2019-06-30 | −$13.1M | −$8.6M | — | — |
| Q1 2019 | 2019-03-31 | −$7.2M | $4.0M | — | — |
| Q4 2018 | 2018-12-31 | −$8.4M | — | — | — |
| Q3 2018 | 2018-09-30 | −$5.0M | — | — | — |
| Q2 2018 | 2018-06-30 | −$4.5M | — | — | — |
| Q1 2018 | 2018-03-31 | −$11.3M | — | — | — |
Kodiak Sciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$87.2M to −$136.5M, a net decrease of $49.3M. Kodiak Sciences's latest reported quarter, Q2 2026, generated −$46.6M in free cash flow, a decrease of $11.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Kodiak Sciences source filings ↗Community posts
Kodiak’s two retinal treatments meet pivotal trial endpoints
Kodiak Sciences ($KOD) reported that Zenkuda and tabirafusp-ted met their primary vision endpoints in the Phase 3 DAYBREAK trial in wet age-related macular degeneration. Both achieved non-inferior vision gains against aflibercept at one yea ...
